Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02841761 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects
A Phase 1 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02841761 is a Phase 1 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT02841761, a Phase 1 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of ACT-132577 on the pharmacokinetics of midazolam and 1-hydroxy midazolam and to evaluate the safety and tolerability of ACT-132577 when administered alone and in combination with midazolam.
Interventions
- DRUG Midalozam
- DRUG Aprocitentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2016-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02841761
The ClinicalTrials.gov registry entry for NCT02841761 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midalozam is the first listed.
NCT02841761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02841761 about?
NCT02841761 is a clinical study titled "A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects". The purpose of this study is to evaluate the effect of ACT-132577 on the pharmacokinetics of midazolam and 1-hydroxy midazolam and to evaluate the safety and tolerability of ACT-132577 when administered alone and in combination with midazolam.
What is the current status of trial NCT02841761?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-07-01. Estimated completion is 2016-10-01.
What interventions are being tested in trial NCT02841761?
The interventions under investigation include: Midalozam (DRUG), Aprocitentan (DRUG).
Who is sponsoring clinical trial NCT02841761?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.